. The main efficacy population was R/R AML patients who received 500 mg of ivonib orally daily and were followed up for at least 6 months
Clin Cancer Res: SD-101 in combination with pembrolizumab in recurrent/metastatic squamous cell carcinoma
Time of Update: 2022-03-04
Median overall survival was approximately 10 months with platinum, 5-fluorouracil, and cetuximab as standard first-line therapy, but more than 80% of patients experienced grade 3 or higher treatment-related adverse events .
Gut Microbiome 101: A Beginner's Guide
Time of Update: 2022-03-02
The new microbes that enter the digestive tract increase the number of species already present, and the abundance of new food provides them with nutrients and makes them easier to reproduce .
Coba Bio's original monoclonal antibody SPX-101 starts phase I clinical trial in the United States
Time of Update: 2022-02-23
According to Professor Spira's previous enrollment records, the clinical trial is expected to be completed by the end of 2022 .
In 2021, my country's human vaccine exports will increase from 1.9 billion to 101 billion, mostly from the export of new crown vaccines
Time of Update: 2022-02-18
According to customs data, the export value of human vaccines in 2021 is about 101 billion yuan, an increase of 5,264.
Sichuan Agricultural University: 101 expert service groups are ready to go
Time of Update: 2022-01-23
"It is very timely and effective. With the support of the scientific and technological service group of agricultural colleges and universities, it is more confident to promote rural
[2021 ASH Express] Focus on the prognosis study of MPN patients and the whole management of MF patients
Time of Update: 2022-01-10
>In univariate analysis, the factors that increase the risk of PMF thrombosis were age (P=0. 013) and JAK2 mutation (P=0. 003). In addition, patients with low-risk and intermediate-risk-1 of IPSS were more likely to have
ATG-101 clinical trial completes first patient dosing in Australia
Time of Update: 2021-12-29
As a new PD-L1/4-1BB bispecific antibody, ATG-101 can block the immunosuppressive PD-L1/PD-1 binding and conditionally activate the 4-1BB costimulatory signal, thereby activating anti-tumor Immune effector cells enhance the safety while enhancing the efficacy of the drug .
Deck Pharmaceuticals obtained US FDA approval of ATG-101 (PD-L1/4-1BB double antibody
Time of Update: 2021-12-09
The approval of the IND enables Deqi Pharmaceuticals to initiate this phase I clinical study, which aims to evaluate the safety and tolerability of ATG-101 in patients with advanced solid tumors and non-Hodgkin's lymphoma .
Peritransplantation treatment with rucotinib improves the prognosis of MF patients
Time of Update: 2021-12-07
>. 1. A tapering strategy should be used to stop rucotinib treatment. Some studies reported that rucotinib was gradually reduced from 14 days to 1 day before HSCT pretreatment, and there were also
of avelumab combined with axitinib or sunitinib in the treatment of advanced renal cell carcinoma (RCC): from the JAVELIN Renal 101 study
Time of Update: 2021-12-04
SunitinibThrough the analysis of the JAVELIN Renal 101 clinical study (NCT02684006), the relationship between baseline NLR and progression-free survival (PFS) and overall survival (OS) in the avelumab combined with axitinib or sunitinib group was analyzed Retrospective analysis .
Compliance of Rucotinib in the treatment of MF patients: an interim analysis of an Italian prospective real world study (ROMEI)
Time of Update: 2021-11-04
in order to improve clinicians' compliance with rucotinib treatment. Pay attention to  . Methods A prospective cohort study. The Morisky Medication Compliance Scale Assessment Medication Compliance Study
Rucotinib combination therapy provides a new solution for the treatment of intolerant or drug-resistant MF patients
Time of Update: 2021-10-21
Figure 2 The results of the study on the proportion of patients with different daily doses show that the rucotinib dosage regimen has a significant effect on spleen shrinkage and symptom improvement in patients with anemic MF.
Deqi Pharmaceuticals will publish the research results of ATG-101 and ATG-017 at the 2021 SITC annual meeting
Time of Update: 2021-10-20
The poster details are as follows:Abstract Number: 227Title: Computational semi-mechanical pharmacology model of PD-L1/4-1BB bispecific antibody ATG-101 for the treatment of solid tumors and non-Hodgkin's lymphoma (NHL)Publication time: November 12-14, 2021, 7:00-17:00 (US Eastern Time)Speaker: Dr.
The Phase II clinical trial application of Celinisolone for the treatment of MF by Deqi Pharmaceuticals was accepted by the NMPA
Time of Update: 2021-08-29
Deck Pharmaceuticals recently announced that the National Medical Products Administration (NMPA) has accepted the world's first oral XPO1 inhibitor selinexor in a phase II clinical trial of monotherapy for patients with myelofibrosis (MF) in China .
Announcement of the Yongzhou Municipal Market Supervision Administration on the 101 batches of food safety supervision and sampling
Time of Update: 2021-08-27
> Hereby publicize . Attachment: 1. Food Safety Supervision
Petrochemical Jingwei Pingqiao 101 Well Perforating Construction Sets National Record
Time of Update: 2021-08-14
levels of 30 . > Over the years, the company has continued to carry out multi-stage perforation technology research, forming high-temperature and high-pressure wells/highly deviated
The Phase I clinical trial application of Deqi Pharmaceutical ATG-101 was approved in Australia
Time of Update: 2021-08-06
announced that the Bellberry Human Research Ethics Committee (HREC) of Australia has approved ATG-101 for the treatment of metastatic or advanced solid tumors and B-cell non-Hodgkin’s lymphoma (B-NHL).